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Abstract
Chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the most important causes of hepatocellular carcinoma
(HCC), accounting for the majority of the cases worldwide. The geographical distribution of HCC therefore coincides with the
distribution of HBV and HCV infections in those areas. Similar to nonviral liver diseases, HBV and HCV infection can cause
chronic injury to the liver, with subsequent progression to severe ﬁbrosis and cirrhosis. The presence of cirrhosis is a major risk
factor for the development of HCC. However, HCC can occur in the absence of cirrhosis, suggesting that both HBV and HCV
may be directly involved in hepatocarcinogenesis. Several HBV factors have been implicated in hepatocarcinogenesis, including the
HBx gene, the pre-S2/S gene and the HBV spliced protein. Furthermore, HBV can be integrated into the host genome, leading to
changes in genomic function or chromosomal instability. By contrast to HBV, HCV cannot integrate into the host genome. Various
HCV proteins, including the core, envelope and nonstructural proteins, have been shown to have oncogenic properties. For HBV
infection, antiviral therapy and vaccination have been shown to decrease the risk of HCC. Antiviral therapy for HCV can also
reduce the risk of HCC.
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Introduction
Hepatocellular carcinoma (HCC) is the ﬁfth most common
malignancy worldwide, with an estimated 500 000–1 000 000
new cases annually [1,2]. The majority of HCC cases (up to
80%) occur in developing countries, with the highest inci-
dence found in sub-Saharan Africa and Southeast Asia [3].
Although the incidence of HCC in developed western coun-
tries is low, there has been an increasing trend over the past
two decades. The geographical variability observed in the
incidence of HCC parallels the incidence of hepatitis B virus
(HBV) and hepatitis C virus (HCV) infections in those areas.
These two viruses constitute the two most important risk
factors for the development of HCC, accounting for over
80% of all HCC globally. Less common risk factors for HCC
include nonviral factors, such as alcohol consumption, aﬂa-
toxin B1, and other chronic liver diseases.
Regardless of the aetiological agent, the development of
HCC can occur though the process of increased hepatocyte
turnover incited by chronic liver injury and regeneration.
The continuous inﬂammation and oxidative stress facilitates
the accumulation of genetic alterations within the hepato-
cyte. As a result, the major risk factor for the development
of HCC is pre-existing cirrhosis [4]. Indeed, chromosomal
abnormalities and a loss of alleles exist in approximately half
of cirrhotic nodules, and direct outgrowth of HCC has been
observed in cirrhotic nodules [5].
Although liver cirrhosis per se can cause HCC, the fact
that HBV, and less commonly, HCV, can cause HCC in the
absence of cirrhosis conﬁrms the inherent oncogenic proper-
ties of these two viruses. Given that HBV is a DNA virus
and HCV is an RNA virus, these two viruses are sufﬁciently
different to cause cancer via different mechanisms at the
molecular level. The mechanisms by which these viruses
cause cancer are likely to involve complex interactions
between the virus and the human host.
In most cancers, carcinogenesis is a multi-step process
with an accumulation of genetic changes that ultimately lead
to malignant transformation. The proposed mechanisms of
HBV- and HCV-related hepatocarcinogenesis are summarized
in Fig. 1.
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Role of HBV
An estimated 350 million people worldwide are chronically
infected with HBV. Of these, up to 40% will develop compli-
cations of cirrhosis and HCC [6]. The annual risk for chronic
HBV carriers is less than 1%, but is higher in those patients
with concurrent cirrhosis (2–3%) [7]. Approximately 70–80%
of HBV-related HCC occurs in cirrhotic livers, whereas the
remainder of the HCC occurs in the absence of underlying
cirrhosis. The increased risk of HCC associated with HBV
infection is especially prominent in areas such as Asia where
HBV is endemic. In this region, HBV is transmitted either at
birth or during the early years of life, thus leading to a high
rate of chronic infection with the persistence of HBV in the
host [8].
HBV in hepatocarcinogenesis
HBV likely causes HCC via both indirect and direct path-
ways. In the former, HBV incites chronic injury to the he-
patocytes, with continuous necro-inﬂammation and
regeneration activity and a resultant increase in hepatocyte
turnover. The net effect of this is the accumulation of poten-
tial critical mutations in the hepatocyte genome, with subse-
quent malignant transformation and clonal expansion, leading
to HCC.
In addition, HBV has been shown to be an oncogenic
virus. The earliest evidence that linked HBV to the develop-
ment of HCC was obtained in the woodchuck hepatitis virus
model in which 100% of the rodents infected with wood-
chuck hepatitis virus developed HCC [9]. Because HBV
contains partially double stranded-DNA, it can directly cause
HCC by integrating its DNA into the host genome. Although
the integration of HBV DNA into the host genome is not
required for its replication, it does allow for the persistence
of the viral genome within the host. This is supported by the
fact that integrated HBV sequences can be found in approxi-
mately 80% of HBV-related HCC, and the integrated viral
DNA is monoclonal in nature in individual tumours [10].
However, HBV integration can also be found in non-HCC
tissue. Integration is usually multiple and occurs at multiple
random sites, and can occur also during the early stages of
infection. HBV integration can have several mutagenic conse-
quences, including large inverted duplications, deletions,
ampliﬁcations and translocation, resulting in chromosomal
instability [11]. Malignant transformation occurs when these
genetic alterations confer a selective growth advantage to
the affected cell. Surprisingly, HBV integration near known
oncogenes appears to be a rare event. HBV can be inte-
grated into genes that are responsible for the control of cell
proliferation and differentiation, such as the human telomer-
ase gene hTERT (regulating cellular immortalization), MAPK1
and the cycline A gene (regulating cellular proliferation), and
the gene for tumour necrosis factor receptor-associated pro-
tein 1 (regulating cellular viability) [10].
Of all the HBV genes, the HBx gene has generated the
most interest in HBV-related hepatocarcinogenesis, and is
the most commonly integrated gene. Over 95% of patients
with HBV-related cirrhosis and dysplasia are positive for
HBx, and HBx is expressed in 70% of patients with HBV-
related HCC. The exact mechanism by which HBx can
induce HCC development remains to be fully elucidated.
FIG. 1. Proposed mechanisms of hepatocarci-
nogenesis related to hepatitis B virus (HBV)
and hepatitis C virus (HCV). HCC, hepatocel-
lular carcinoma.
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HBx is known to be a transcription activator through its
interaction with a wide range of both viral and host regula-
tory elements [12]. These include the major histocompatibil-
ity complex, epidermal growth factor receptor, c-myc, c-jun,
c-fos, TP53, AP-1, NF-KB and SP1, among others [13–15].
Through its effect on these regulator elements, HBx can
interfere with the hepatocyte DNA repair system and the
controlling elements of cellular proliferation [16]. In addition,
HBx can bind with p53, with subsequent inhibition of p53-
mediated apoptosis [17].
In addition to the HBx gene, other HBV gene elements
integrating into the host genome have been incriminated in
hepatocarcinogenesis. These include the truncated pre-S2/S
gene, which encodes a group of regulatory proteins called
transcription activators (PreS2) and also encodes the enve-
lope proteins (LHBs, MHBs and SHBs) [18]. The PreS2 tran-
scription activators undergo phosphorylation by protein
kinase C, with subsequent activation of the signalling
pathways responsible for activation of transcription factors
AP-1 and NF-jB. Activation of these pathways may cause an
increase in hepatocyte proliferation. In addition, overproduc-
tion of the envelope proteins, particularly LHBs and MHBs,
may lead to over-accumulation in the cytoplasm of the
hepatocytes, causing the histological appearance of ground-
glass hepatocytes [19]. This in turn may cause cellular stress,
with predisposition of the cells to undergo malignant
transformation.
Another HBV protein, known as the HBV spliced protein,
is expressed in chronic hepatitis B (CHB) infection. It has
been suggested that this spliced protein can induce apoptosis
and modulate signalling via the transforming growth factor
pathway, and thus represents a novel way of promoting liver
ﬁbrosis and hepatocarcinogenesis [20].
Clinical viral factors
Apart from the complex mechanisms of hepatocarcinogene-
sis at the molecular level, several viral factors are associated
with the increased risk of HCC development in the clinical
setting. The most important and perhaps most clinically rele-
vant is the level of serum HBV DNA. Large cohort studies
have shown that higher levels of HBV DNA were associated
with an increased risk of HCC [21,22]. A cut-off level of
>2000 IU/mL was shown to be a strong predictor of HCC,
although even lower HBV DNA levels still indicated a risk
of HCC development [21,23]. Given that HBV is likely to
have an oncogenic property, it is not surprising that, the
higher the HBV DNA (signifying higher viral replication), the
higher the risk of developing HCC. Although HBeAg positiv-
ity had previously been considered as a risk factor, it has
not been shown to be an independent predictor of HCC in
subsequent studies, and its effect is likely dependent on both
the underlying HBV DNA levels and the HBV genotypes
[21,24]. There are eight HBV genotypes (A–H), which are
based on the genomic sequence divergence. Both genotype
C and a high viral load have been shown to be independent
predictors of HCC development [21,25]. The core pro-
moter variants of HBV (A1762T and G1764A) have also
been shown to be associated with the development of HCC
[26,27].
Prevention of HBV-related HCC
The most effective measure of prevention of HBV-related
HCC is the prevention of HBV infection by vaccination. A
universal vaccination programme in Taiwan was demon-
strated to be effective in reducing the rate of childhood
HCC subsequent to its introduction [28]. Through a reduc-
tion of the seroprevalence of HBV in the general population,
the incidence of HCC is likely to decline signiﬁcantly, espe-
cially in areas where HBV is endemic.
In patients already infected with HBV, antiviral therapy
remains the best strategy. Treatment with lamivudine has
been shown to reduce the incidence of HCC in both cir-
rhotic and noncirrhotic CHB patients, although the effect is
blunted with the development of resistance to lamivudine
[29,30]. Given the importance of elevated HBV DNA as a
highly signiﬁcant and independent risk factor for HCC devel-
opment, it is likely that the reduction of HCC risk is largely
a result of the reduction of HBV DNA. With more potent
antiviral drugs available (such as entecavir and tenofovir),
long-term HBV DNA suppression is now possible, with a
very low risk of drug resistance.
Role of HCV
There are an estimated 170 million people worldwide
infected with HCV, of whom approximately 20% will pro-
gress to cirrhosis [31]. By contrast to CHB, patients with
chronic hepatitis C (CHC) almost always develop HCC in
the presence of established cirrhosis. The annual risk of
HCC development in CHC patients with cirrhosis is in the
range of 1–4%, and an estimated 1–3% of patients chronically
infected with HCV will develop HCC after 30 years [32].
There is an increasing incidence of cases of HCC observed
in the Western population, the majority of which are HCV-
related, and the incidence is contributed to by an ageing
population. Similar to HBV, the association between HCV
and HCC is likely a combination of the independent effect
of HCV on hepatocarcinogenesis and the indirect effect of
cirrhosis.
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HCV in carcinogenesis
The HCV is a positive-stranded RNA virus containing
approximately 9500 nucleotides. The genome is organized
into three structural proteins at the N-terminal end and four
functional proteins at the C-terminal end. The structural
proteins are the core (C) and envelope 1 and 2 proteins (E1
and E2, respectively), whereas the nonstructural (NS) pro-
teins include NS2, NS3, NS4 and NS5. Unlike HBV, HCV
lacks reverse transcriptase activity, and therefore HCV does
not integrate into the host genome. Because the HCV is a
completely cytoplasmic-replicating virus, the main hypothesis
for HCV carcinogenesis is that it occurs via indirect path-
ways through the effects of chronic inﬂammation and hepa-
tocellular injury. This is likely the major mechanism of
hepatocarcinogenesis in HCV-related HCC; this assumption
is supported by the fact that the presence of cirrhosis is
almost a pre-requisite for HCC development.
However, it is unlikely that necro-inﬂammation alone is
sufﬁcient to cause HCC. In conditions such as autoimmune
hepatitis, despite chronic inﬂammation and liver injury,
HCC development is rare. Moreover, HCC can still
develop in a very small proportion of non-cirrhotic patients
with CHC, implicating a more direct effect from the HCV
itself.
Various HCV proteins have been reported to have a role
in HCC development in experimental studies involving cell
culture systems and animal models. The HCV core protein is
involved in viral particle assembly and generation of complete
virions. However, the core protein is also involved in cell sig-
nalling, transcription activation, apoptosis, lipid metabolism
and transformation [33]. In transgenic mice models, the HCV
core protein has been shown to induce HCC, although the
exact mechanism by which it does so remains unclear [34].
One of the potential mechanisms includes induction of oxida-
tive stress. The HCV core protein has been shown to induce
reactive oxygen species in the absence of inﬂammation. The
oxidative stress may decrease metabolic processes within
the mitochondria, with a decline in microsomal triglyceride
transfer protein activity, resulting in the development of stea-
tosis [35]. The HCV core protein has also been shown to
affect the modulation of cellular gene products and several
cellular regulatory pathways involved in cellular proliferation,
cell cycle control and tumour formation [33]. The HCV core
protein can bind to p53 and pRb tumour suppressor pro-
teins, modulate the expression of p21/Waf, which is involved
in cell cycle control, and interact with cytoplasmic signal
transduction molecules to regulate transcription [36].
Apart from the core proteins, other HCV proteins have
also been shown to contribute to hepatocarcinogenesis. The
E2 protein can interact with CD81 and inhibit T and NK
cells, thereby promoting cell survival and proliferation. The
HCV NS3 protein is a multifunctional protein with protease,
RNA helicase and NTPase activity. NS3 can promote hepato-
carcinogenesis by its interaction with certain cellular
proteins, such as p21 and p53 [37]. HCV NS5A, a mem-
brane-associated protein, is involved in the replication of the
HCV genome. The intact NS5A is cytoplasmic and bound to
membranes. However, the truncated form of HCV NS5A
can become localized to the nucleus to act as a transcrip-
tional activator. NS5A can also interact with cellular signal-
ling components and regulatory protein kinases, leading to
the suppression of the host immune response and inhibition
of apoptosis [38]. Therefore, an association between HCV
and HCC is likely to be a result of a combination of the
independent effect of HCV on hepatocarcinogenesis and the
indirect effect of cirrhosis.
Risk factors in HCV-related HCC
The intake of alcohol in patients with CHC synergistically
increases the risk of HCC development, and has a dose-
related effect [39–41]. Co-infection with HBV also synergisti-
cally increases the risk of HCC. A meta-analysis showed
that HBV/HCV co-infection was associated with a 135-fold
increased risk of HCC compared to HBV and HCV mono-
infection (20- and 24-fold increase, respectively), with the
highest risk being in those patients with established cirrhosis
[42]. In cases of co-infection with HIV/HCV, HCC is more
likely to occur at a younger age and with a shorter duration
of HCV infection compared to those with either HCV or
HIV mono-infection [43]. The role of the HCV genotype is
less clear, although some studies have shown an increased
risk of HCC in patients infected with genotype 1b
[39,44,45]. There is some evidence indicating that schisto-
somiasis may increase the risk of more severe disease in
patients infected with HCV genotype 4 compared to those
without parasitic infection [46]. The role of obesity and
diabetes mellitus in the risk of HCC in patients with CHC
remains to be fully determined, although there is some
evidence that both may increase the risk [47–49].
Prevention of HCV-related HCC
Unlike HBV, there are currently no effective vaccination
strategies to prevent HCV infection. The HCV polymerase
enzyme lacks proofreading capabilities, which results in the
profound genomic diversity of HCV. Accordingly, it is
extremely difﬁcult to produce a single effective vaccine.
However, with the screening of HCV in blood transfusion
services, transfusion-related HCV infection has been lowered
to almost zero [50]. This has an obvious bearing on the
future incidence of HCV infection in developed countries.
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Interferon-based therapy is currently the standard of care
for patients with CHC, and has been proven to be effective
in eliminating HCV. Both conventional and pegylated inter-
feron (IFN) therapy have been used widely, with the aim of
achieving a sustained virological response (SVR). In a meta-
analysis of 11 studies with 2178 patients, investigating the
incidence of HCC in patients with HCV-related cirrhosis,
there was a higher rate of HCC in untreated patients com-
pared to IFN-treated patients (21.5% vs. 8.2%, respectively;
OR 3.0, 95% CI 2.3–3.9). This effect was observed irrespec-
tive of whether the patients achieved SVR or not, although
the effect was greater when SVR was achieved [51]. In
another cohort study, treatment with conventional IFN in
noncirrhotic patients infected with HCV reduced the risk of
HCC by 50%, and further down to 20% in those patients
who achieved SVR [52]. In another large cohort study of
2166 patients, there was a signiﬁcantly lower rate of HCC
after 15 years of follow-up in those who received IFN ther-
apy compared to those not treated (13.9% vs. 23.9%, respec-
tively, p <0.001). In those patients who achieved SVR, the
rate was even lower (1.9% at 15 years) [53]. Therefore, the
current treatment model for CHC appears to be effective in
reducing the risk of HCC in patients infected with HCV,
with the largest beneﬁt observed in the group of patients
who achieve SVR.
Occult HBV Infection
Occult HBV infection is deﬁned by the persistence of HBV
DNA in the liver and/or serum without detectable serum
hepatitis B surface antigen. Occult HBV has been implicated
in HCC development because the highest rates of occult
HBV infection have been found in patients with HCC, espe-
cially in those infected with HCV and those with alcoholic
liver disease [54–56]. In these cases of HCC, HBV DNA has
been detected in both tumourous and nontumourous tissue
[57]. In addition, HBx protein expression and cis-activation
can be found in the tumour cells of patients with HCC and
evidence of occult HBV infection [58–60]. This suggests that
the mechanism of hepatocarcinogenesis of occult HBV infec-
tion is similar to that of patients who are positive for hepati-
tis B surface antigen, and that the persistence of HBV DNA
is a risk factor for the subsequent development of HCC.
Conclusions
Hepatocarcinogenesis is a multi-step process involving the
accumulation of different genetic changes, which lead to
malignant transformation and uncontrolled proliferation.
Although many potential pathways and mechanisms have
been identiﬁed in this complex sequence of events, these
have only been largely studied in experimental models and in
small series involving human subjects. Whether these ﬁndings
obtained in vitro can be extrapolated to the in vivo environ-
ment is debatable, and the true clinical and biological rele-
vance of these ﬁndings remains to be determined. Therefore,
despite the progress made in recent decades, a coherent
model of the molecular pathogenesis of HCC relating to
HBV and HCV is still lacking. Future research should con-
tinue to identify aberrant genes and their protein products,
as well as other risk factors, so that novel therapeutic agents
may be developed.
However, it is encouraging that the currently available
antiviral therapy and vaccination for HBV appear to be
effective in lowering the risk of HCC development. Given
the high mortality rate associated with HCC, prevention is
of paramount importance. In addition, screening pro-
grammes for at-risk individuals increase the opportunities
for earlier curative intervention, with an improvement in
long-term survival. Therefore, it is essential that available
effective management strategies are employed, including a
universal HBV vaccination programme and the identiﬁcation
of patients infected with HBV and HCV who may beneﬁt
from antiviral therapy.
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